Glands

Aeterna Zentaris Reports Second Quarter 2021 Financial Results and Provides Pipeline Program Updates

Retrieved on: 
Wednesday, August 4, 2021
Hormones, Endocrine system, Glands, Parathyroid gland, Parathyroid hormone, PTH

TORONTO, ONTARIO, Aug. 04, 2021 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products, today reported its financial and operating results for the second quarter ended June 30, 2021. The Company also provided an update on its pre-clinical and clinical development programs.

Key Points: 
  • TORONTO, ONTARIO, Aug. 04, 2021 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (Aeterna or the Company), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products, today reported its financial and operating results for the second quarter ended June 30, 2021.
  • In consultation with The University of Sheffield, UK, selected AEZS-150 as the lead candidate in the Company's delayed clearance parathyroid hormone fusion polypeptides (DC-PTH) program.
  • In February 2021, Aeterna entered into an exclusive option agreement with Julius-Maximilians-University to evaluate a preclinical, potential COVID-19 vaccine developed at Julius-Maximilians-University.
  • The Company had $69.9 million cash and cash equivalents at June 30, 2021 (March 31, 2021 73.4 million).

Entera Bio to Conduct Conference Call on June 30 to Discuss Phase 2 Results for EB613 Positioned to be the First Oral Bone-Building Agent for the Treatment of Osteoporosis

Retrieved on: 
Monday, June 28, 2021
Hormones, Branches of biology, Endocrine system, Glands, Parathyroid gland, Osteoporosis, Parathyroid hormone

EB613 is an oral formulation of human parathyroid hormone (1-34), or PTH, and is positioned to be the first oral bone building (anabolic) product to treat osteoporosis patients.

Key Points: 
  • EB613 is an oral formulation of human parathyroid hormone (1-34), or PTH, and is positioned to be the first oral bone building (anabolic) product to treat osteoporosis patients.
  • Dr. Tripto-Shkolnik will provide context on the results of the study and the benefits of an oral drug to treat osteoporosis.
  • The conference call will take place on Wednesday, June 30, 2021 from 12-1pm EDT and will include a question-and-answer session.
  • Entera cautions investors not to rely too heavily on the forward-looking statements Entera makes or that are made on its behalf.

Thyroid Cancer Pipeline Insight Report 2021 - ResearchAndMarkets.com

Retrieved on: 
Thursday, June 24, 2021
Pharmaceutical, Health, Oncology, Anatomy, Thyroid disease, Branches of biology, Organs anatomy), Endocrine diseases, Endocrine system, Glands, Thyroid, Pipeline, Drug pipeline

The "Thyroid Cancer - Pipeline Insight, 2021" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Thyroid Cancer - Pipeline Insight, 2021" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • This "Thyroid cancer - Pipeline Insight, 2021" report provides comprehensive insights about 35+ companies and 35+ pipeline drugs in Thyroid cancer pipeline landscape.
  • This segment of the report provides insights about the different Thyroid cancer drugs segregated based on following parameters that define the scope of the report, such as:
    There are approx.
  • Thyroid cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.

Novo Nordisk receives FDA approval for Wegovy™ to treat adults with obesity based on unprecedented efficacy for a prescription medicine in clinical trials

Retrieved on: 
Friday, June 4, 2021
Anatomy, Branches of biology, Health, Thyroid disease, Endocrine diseases, Aging-associated diseases, Endocrine system, Glands, Thyroid, Weight loss, Medication, Cancer

Expanding safe and clinically effective treatment options for obesity management is good news for people with obesity and the medical community."

Key Points: 
  • Expanding safe and clinically effective treatment options for obesity management is good news for people with obesity and the medical community."
  • It is not known if Wegovy is safe and effective when taken with other prescription, over-the- counter, or herbal weight loss products.
  • In studies with rodents, Wegovy and medicines that work like Wegovy caused thyroid tumors, including thyroid cancer.
  • Do not use Wegovy if:
    you have had a serious allergic reaction to semaglutide or any of the ingredients in Wegovy.

Ascendis Pharma A/S Invites the Public to Attend “A Story of Courage: Living with Hypoparathyroidism” in Support of World Hypopara Awareness Day on June 1, 2021

Retrieved on: 
Friday, May 28, 2021
Rare diseases, Anatomy, Medical specialties, Branches of biology, Electrolyte disturbances, Glands, Parathyroid gland, Hypoparathyroidism, Parathyroid hormone, Hypocalcemia, Endocrine system, Endocrine disease

The live, online event seeks to raise awareness of hypoparathyroidism worldwide and share Ariana Feiners uplifting message of hope and inspiration to those affected by chronic illness.

Key Points: 
  • The live, online event seeks to raise awareness of hypoparathyroidism worldwide and share Ariana Feiners uplifting message of hope and inspiration to those affected by chronic illness.
  • Hypoparathyroidism (HP) is a rare endocrine disorder characterized by insufficient levels of parathyroid hormone (PTH), resulting in low calcium and elevated phosphate levels in the blood.
  • Ascendis Pharma currently has a pipeline of three independent endocrinology rare disease product candidates and one oncology product candidate in clinical development.
  • Ascendis,Ascendis Pharma, theAscendis Pharmalogo, the company logo and TransCon are trademarks owned by theAscendis Pharma Group.

Global Thyroid Cancer Markets, Epidemiology and Patient Flow Analysis Report 2020-2035 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, May 25, 2021
Pharmaceutical, Health, Oncology, Other Health, Anatomy, Thyroid disease, Organ systems, Glands, Endocrine diseases, Aging-associated diseases, Thyroid cancer, Thyroid, Cancer, Computed tomography of the thyroid, Thyroid nodule

The "Global Thyroid Cancer Epidemiology and Patient Flow - 2021" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Thyroid Cancer Epidemiology and Patient Flow - 2021" report has been added to ResearchAndMarkets.com's offering.
  • Global Thyroid Cancer Epidemiology and Patient Flow Analysis - 2021, provides Thyroid Cancer epidemiology, demographics, and patient flow.
  • The research provides population data to characterize Thyroid Cancer patients, history of the disease at the population level (Thyroid Cancer prevalence, Thyroid Cancer incidence) and at the clinical level (from diagnosis to treated patients).
  • Demographics: Thyroid Cancer patients by age group, gender
    The data from this research will help executives:
    Establish basis for Thyroid Cancer market sizing, assessing market potential, and developing drug forecast models
    Identify Thyroid Cancer patients segments through age groups, gender, and disease sub-types
    Evaluate Thyroid Cancer market opportunities, identify target patient population
    View source version on businesswire.com: https://www.businesswire.com/news/home/20210525005754/en/

Amolyt Pharma to Present New Phase 1 Data on AZP-3601, its Parathyroid Hormone Analog for Hypoparathyroidism, and Preclinical Data on AZP-3404 at Upcoming Scientific Conferences

Retrieved on: 
Tuesday, May 18, 2021
Anatomy, Branches of biology, Organ systems, Endocrine system, Rare diseases, Glands, Parathyroid gland, Kidney, Hypoparathyroidism, Glucose

In addition, Amolyt will present two retrospective Natural History Study methods to identify patients with chronic hypoparathyroidism.

Key Points: 
  • In addition, Amolyt will present two retrospective Natural History Study methods to identify patients with chronic hypoparathyroidism.
  • Finally, Amolyt will present preclinical data for AZP-3404, a peptide with a new and unique potential mechanism of action on fat and glucose metabolism.
  • At ISPOR 2021, Amolyt will present proposed methods to identify patients with chronic hypoparathyroidism using claims data in the United States (US).
  • Clinical manifestations of hypoparathyroidism vary and impact a large number of tissues and organ systems, including the muscles, brain, heart, and kidneys.

MEDO receives FDA approval to Revolutionize Thyroid Ultrasound.

Retrieved on: 
Thursday, May 6, 2021
Anatomy, Branches of biology, Thyroid disease, Endocrine system, Glands, Thyroid, Nodule, Medo, Thyroid cancer

This high volume is due to the fact that lumps, or "nodules" on the thyroid gland are common and although usually benign, can be cancerous.

Key Points: 
  • This high volume is due to the fact that lumps, or "nodules" on the thyroid gland are common and although usually benign, can be cancerous.
  • Using artificial intelligence, Medo has revolutionized the process of performing thyroid studies and turned it into a seamless, fast,and objective workflow.\nWith Medo-Thyroid, the user simply obtains quick video \'sweeps\' of each side of the thyroid gland.
  • Jacob Jaremko, a radiologist and co-founder of Medo, explains that "Medo-Thyroid makes thyroid ultrasound a less frustrating test, by presenting thyroid measurements and nodule characteristics in a convenient format.
  • Dornoosh Zonoobi, co-founder and CEO of Medo, notes that: "With this product, Medo provides both clinical and financial value to the stakeholders.

New Study Confirms the Stability and Potency of a Novel Formulation of Liquid Levothyroxine

Retrieved on: 
Friday, April 30, 2021
Anatomy, Glands, Thyroid, Levothyroxine, Norfloxacin, Thyroid hormones, Pharmacy

This study adds to previously published data and questions the stability and potency of extemporaneously "compounded" liquid levothyroxine formulations by comparing and analyzing the stability and potency of a novel liquid levothyroxine formulation, Tirosint-SOL, which is packaged in patented precise monodose ampules.\nThe new study was conducted by researchers at the Campbell University College of Pharmacy & Health Sciences.

Key Points: 
  • This study adds to previously published data and questions the stability and potency of extemporaneously "compounded" liquid levothyroxine formulations by comparing and analyzing the stability and potency of a novel liquid levothyroxine formulation, Tirosint-SOL, which is packaged in patented precise monodose ampules.\nThe new study was conducted by researchers at the Campbell University College of Pharmacy & Health Sciences.
  • "The inconsistent product potency exhibited by compounded formulations should be of great concern to clinicians, patients and public health officials.
  • By comparison, our new study shows that a novel formulation of levothyroxine liquid, Tirosint-SOL packaged in a unique monodose ampule demonstrated consistent and predictable levels of potency and stability.
  • Tirosint-SOL is the only FDA-approved liquid levothyroxine formulation available in monodose packaging for convenience and dosing precision.

Acella Pharmaceuticals, LLC, Issues Voluntary Nationwide Recall of Certain Lots of NP Thyroid® (Thyroid Tablets, USP) Due to Sub Potency

Retrieved on: 
Thursday, April 29, 2021
Anatomy, Glands, Endocrine system, Thyroid, Desiccated thyroid extract, Thyroid hormones, Hyperthyroidism, Levothyroxine, Liothyronine, Hypothyroidism, Palpitations

b"ATLANTA, April 29, 2021 /PRNewswire/ --Acella Pharmaceuticals, LLC, is voluntarily recalling certain lots listed in the Tables 1 and 2 below of 15-mg, 30-mg, 60-mg, 90-mg and 120-mg NP Thyroid, Thyroid Tablets, USP [levothyroxine (T4) and liothyronine (T3)] to the consumer level.

Key Points: 
  • b"ATLANTA, April 29, 2021 /PRNewswire/ --Acella Pharmaceuticals, LLC, is voluntarily recalling certain lots listed in the Tables 1 and 2 below of 15-mg, 30-mg, 60-mg, 90-mg and 120-mg NP Thyroid, Thyroid Tablets, USP [levothyroxine (T4) and liothyronine (T3)] to the consumer level.
  • The products are being recalled because routine testing has found these lots to be sub potent.
  • There is reasonable risk of serious injury in newborn infants or pregnant women with hypothyroidism including early miscarriage, fetal hyperthyroidism, and/or impairments to fetal neural and skeletal development.
  • In elderly patients and patients with underlying cardiac disease toxic cardiac manifestations of hyperthyroidism may occur, such as cardiac pain, palpitations or cardiac arrhythmia.